Sandoz, a global leader in generic and biosimilar medicines, has launched generic rivaroxaban in Germany in new 10 mg, 15 mg, and 20 mg strengths, providing patients with a high-quality and more affordable alternative to Bayer’s branded Xarelto. This launch follows successful litigation by Sandoz, which challenged the dosage patent protecting the higher strengths of rivaroxaban, revoked in July 2025.
Previously, only the 2.5 mg strength of generic rivaroxaban was available after the main patent expired in April 2024, while Bayer continued to sell the more widely used higher strengths at monopoly prices due to preliminary injunctions. With the patent challenge resolved, Sandoz can now offer a comprehensive range of rivaroxaban doses, marking a significant milestone for expanding patient access.
Thomas Weigold, Country President Germany, highlighted the importance of the launch, noting that the patent challenge ended a 16-month delay that had cost patients and the healthcare system unnecessary expenses.
Rivaroxaban – 1 A Pharma is used for stroke prevention in adults with non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis and pulmonary embolism, and prevention of venous thromboembolism after hip or knee surgery. The new launch further supports affordability and access through participation in Germany’s open-house discount agreements.
This move strengthens Sandoz’s position as a key player in providing cost-effective anticoagulant therapies in the German market.